Clinical trial
A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors…
NCT00198159 · Indiana University School of Medicine, Other · Terminated
Key facts
| NCT number | NCT00198159 |
|---|---|
| Title | A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR |
| Official title | A Phase II Study of ZD1839 (Iressa)in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR) |
| Acronym | IUCRO-0021 |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | AstraZeneca Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Germ Cell Tumors Expressing EGRF |
| Intervention type | Drug |
| Interventions | ZD1839 Iressa |
| Enrollment | 21 |
| Start date | Sep 1, 2002 |
| Primary completion | Feb 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Sep 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: